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                        PROGRESS WITH THE PfSPZ MALARIA VACCINE 
 
There has been substantial progress in the control of malaria during the past decade but it is 
estimated that in 2015 there were still 429,000 (uncertainty interval 235-639,000) deaths 
from malaria, mainly in African children,1 and current gains are threatened by the 
emergence of artemisinin and insecticide resistance.  New tools, including malaria vaccines, 
are needed. The malaria vaccine RTS,S/AS01 has so far attracted the most attention, as it is 
the first malaria vaccine to obtain a positive approval from a regulatory authority 2 following 
a long period of development and evaluation.3  However, during this period, substantial 
progress has been made with the development of several other malaria vaccines, including 
the Plasmodium falciparum sporozoite vaccine PfSPZ.  
In this edition of Lancet Infectious Diseases Sissoko, Healy  and colleagues report the results 
of one of the first efficacy trials of this vaccine undertaken in a malaria endemic country.4 
The development of PfSPZ has been based on the observation made in the 1970s that 
immunisation with irradiated  sporozoites, delivered through the bites of over 1,000 
infected mosquitoes, provided protection against challenge from a mosquito infected with 
viable sporozoites.5 Irradiated sporozoites undergo partial development in liver cells to form 
a schizont, which induces an immune response,  but which dies before rupturing  into the 
blood stream and releasing the blood stage parasites which cause symptoms. Development 
of a vaccine based on irradiated sporozoites was for many years considered to be 
impractical because of the need for delivery by mosquito bite and a requirement to store 
the vaccine at a very low temperature.  However, with courage and persistence, Hoffman 
and his colleagues at Sanaria have overcome these challenges by developing novel methods 
2 
 
for producing purified sporozoite, and for storing and distributing them using a system 
based on liquid nitrogen. Many trials of PfSPZ have now been conducted in non-immune 
volunteers in order to define an optimum dose and route of administration. During a recent 
trial, 7/10 American volunteers immunised intravenously five times with 2.7x105 sporozites 
were protected six months after vaccination against challenge with a homologous strain of 
parasite to that used in making the vaccine but only 1 of 10 challenged with a heterologous 
strain was protected,6 the kind of challenge likely to occur in malaria endemic populations. 
In the study reported by Sissoko and Healy,4 46 healthy adult Malians were vaccinated 
intravenously with five doses of 2.7 x 105 irradiated sporozoites and 47 controls received a 
placebo.  The vaccine was safe and extremely well tolerated, producing minimal local or 
systemic side effects and only 1 of 502 intravenous injections had to be repeated.  Efficacy 
was not as high as that seen in the American volunteers (48.3% [95% CI 14.5, 68.7]) when 
measured against first infection and 28.8% [95% CI 8.2, 47.2] against all infections during the 
five month follow-up period. The geometric mean titre of antibody to the circumsporozoite 
protein on the surface of the sporozoite, a partial correlate of protection, was substantially 
lower in the Malian volunteers than observed in American adults,  suggesting that prior 
exposure to malaria may have down regulated the immune response to the malaria 
antigens delivered through the vaccine.7 Recent immunological studies have provided 
evidence to support this hypothesis with demonstration that malaria exposed individuals 
have an increased population of atypical memory B cells and a depletion of follicular helper 
T cells, which are important for development of immunological memory.8,9 Potential ways of 
overcoming this challenge for PfSPZ are administration of an increased dose and  
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vaccination of children before they are exposed to malaria, approaches  that are now being 
explored.10                
Although most experience has been obtained with sporozoites attenuated by irradiation, 
parallel studies are being undertaken with sporozoites attenuated by genetic engineering11 
or by administration of viable sporozoites under cover of administration of chloroquine.12   
These approaches allow more complete development of the liver schizont than irradiated 
sporozoites and hence a broader immune response. Genetically modified sporozoite 
vaccines could be produced using the same manufacturing processing developed for PFSPZ. 
PfSPZ is a very promising malaria vaccine candidate which is likely to be deployed first in the 
military and travellers and perhaps in mass vaccination campaigns targeting elimination. 
Whether it can become part of the routine expanded programme of immunisation 
programme in highly malaria endemic countries, such as Mali, requires further research.   
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